329 related articles for article (PubMed ID: 28732819)
1. Individual dose adjustment of riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Hill NS; Rahaghi FF; Sood N; Frey R; Ghofrani HA
Respir Med; 2017 Aug; 129():124-129. PubMed ID: 28732819
[TBL] [Abstract][Full Text] [Related]
2. Riociguat for the treatment of pulmonary arterial hypertension.
Ghofrani HA; Galiè N; Grimminger F; Grünig E; Humbert M; Jing ZC; Keogh AM; Langleben D; Kilama MO; Fritsch A; Neuser D; Rubin LJ;
N Engl J Med; 2013 Jul; 369(4):330-40. PubMed ID: 23883378
[TBL] [Abstract][Full Text] [Related]
3. Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Bishop BM
Am J Health Syst Pharm; 2014 Nov; 71(21):1839-44. PubMed ID: 25320133
[TBL] [Abstract][Full Text] [Related]
4. Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Results from a phase II long-term extension study.
Halank M; Hoeper MM; Ghofrani HA; Meyer FJ; Stähler G; Behr J; Ewert R; Fletcher M; Colorado P; Nikkho S; Grimminger F
Respir Med; 2017 Jul; 128():50-56. PubMed ID: 28610669
[TBL] [Abstract][Full Text] [Related]
5. Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial.
Simonneau G; D'Armini AM; Ghofrani HA; Grimminger F; Jansa P; Kim NH; Mayer E; Pulido T; Wang C; Colorado P; Fritsch A; Meier C; Nikkho S; Hoeper MM
Lancet Respir Med; 2016 May; 4(5):372-80. PubMed ID: 27067478
[TBL] [Abstract][Full Text] [Related]
6. Riociguat: a novel new drug for treatment of pulmonary hypertension.
Makowski CT; Rissmiller RW; Bullington WM
Pharmacotherapy; 2015 May; 35(5):502-19. PubMed ID: 26011143
[TBL] [Abstract][Full Text] [Related]
7. Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension.
Lian TY; Jiang X; Jing ZC
Drug Des Devel Ther; 2017; 11():1195-1207. PubMed ID: 28458514
[TBL] [Abstract][Full Text] [Related]
8. Riociguat for the treatment of pulmonary hypertension.
Meis T; Behr J
Expert Opin Pharmacother; 2014 Nov; 15(16):2419-27. PubMed ID: 25260791
[TBL] [Abstract][Full Text] [Related]
9. Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study).
Marra AM; Halank M; Benjamin N; Bossone E; Cittadini A; Eichstaedt CA; Egenlauf B; Harutyunova S; Fischer C; Gall H; Ghofrani HA; Hoeper MM; Lange TJ; Olsson KM; Klose H; Grünig E
Respir Res; 2018 Dec; 19(1):258. PubMed ID: 30567595
[TBL] [Abstract][Full Text] [Related]
10. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension.
Ghofrani HA; D'Armini AM; Grimminger F; Hoeper MM; Jansa P; Kim NH; Mayer E; Simonneau G; Wilkins MR; Fritsch A; Neuser D; Weimann G; Wang C;
N Engl J Med; 2013 Jul; 369(4):319-29. PubMed ID: 23883377
[TBL] [Abstract][Full Text] [Related]
11. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2).
Simonneau G; D'Armini AM; Ghofrani HA; Grimminger F; Hoeper MM; Jansa P; Kim NH; Wang C; Wilkins MR; Fritsch A; Davie N; Colorado P; Mayer E
Eur Respir J; 2015 May; 45(5):1293-302. PubMed ID: 25395036
[TBL] [Abstract][Full Text] [Related]
12. Change of right heart size and function by long-term therapy with riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Marra AM; Egenlauf B; Ehlken N; Fischer C; Eichstaedt C; Nagel C; Bossone E; Cittadini A; Halank M; Gall H; Olsson KM; Lange TJ; Grünig E
Int J Cardiol; 2015 Sep; 195():19-26. PubMed ID: 26011408
[TBL] [Abstract][Full Text] [Related]
13. Riociguat for patients with chronic thromboembolic pulmonary hypertension: Usefulness of transitioning from phosphodiesterase type 5 inhibitor.
Yamamoto K; Tanabe N; Suda R; Sasaki A; Matsumura A; Ema R; Kasai H; Kato F; Sekine A; Nishimura R; Jujo T; Sugiura T; Shigeta A; Sakao S; Tatsumi K
Respir Investig; 2017 Jul; 55(4):270-275. PubMed ID: 28705306
[TBL] [Abstract][Full Text] [Related]
14. Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension.
Kim NH; D'Armini AM; Grimminger F; Grünig E; Hoeper MM; Jansa P; Mayer E; Neurohr C; Simonneau G; Torbicki A; Wang C; Fritsch A; Davie N; Ghofrani HA
Heart; 2017 Apr; 103(8):599-606. PubMed ID: 28011757
[TBL] [Abstract][Full Text] [Related]
15. Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors.
Hoeper MM; Klinger JR; Benza RL; Simonneau G; Langleben D; Naeije R; Corris PA
Respir Med; 2017 Jan; 122 Suppl 1():S18-S22. PubMed ID: 27887774
[TBL] [Abstract][Full Text] [Related]
16. Use of responder threshold criteria to evaluate the response to treatment in the phase III CHEST-1 study.
D'Armini AM; Ghofrani HA; Kim NH; Mayer E; Morsolini M; Pulido-Zamudio T; Simonneau G; Wilkins MR; Curram J; Davie N; Hoeper MM
J Heart Lung Transplant; 2015 Mar; 34(3):348-55. PubMed ID: 25813765
[TBL] [Abstract][Full Text] [Related]
17. Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study.
McLaughlin VV; Jansa P; Nielsen-Kudsk JE; Halank M; Simonneau G; Grünig E; Ulrich S; Rosenkranz S; Gómez Sánchez MA; Pulido T; Pepke-Zaba J; Barberá JA; Hoeper MM; Vachiéry JL; Lang I; Carvalho F; Meier C; Mueller K; Nikkho S; D'Armini AM
BMC Pulm Med; 2017 Dec; 17(1):216. PubMed ID: 29282032
[TBL] [Abstract][Full Text] [Related]
18. Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry.
Ghofrani HA; Gomez Sanchez MA; Humbert M; Pittrow D; Simonneau G; Gall H; Grünig E; Klose H; Halank M; Langleben D; Snijder RJ; Escribano Subias P; Mielniczuk LM; Lange TJ; Vachiéry JL; Wirtz H; Helmersen DS; Tsangaris I; Barberá JA; Pepke-Zaba J; Boonstra A; Rosenkranz S; Ulrich S; Steringer-Mascherbauer R; Delcroix M; Jansa P; Šimková I; Giannakoulas G; Klotsche J; Williams E; Meier C; Hoeper MM;
Respir Med; 2021 Mar; 178():106220. PubMed ID: 33540340
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of riociguat in the treatment of chronic thromboembolic pulmonary arterial hypertension: A meta-analysis.
Ying M; Song J; Gu S; Zhao R; Li M
Medicine (Baltimore); 2021 Jun; 100(22):e26211. PubMed ID: 34087896
[TBL] [Abstract][Full Text] [Related]
20. Riociguat for pulmonary hypertension.
Ghofrani HA; Voswinckel R; Gall H; Schermuly R; Weissmann N; Seeger W; Grimminger F
Future Cardiol; 2010 Mar; 6(2):155-66. PubMed ID: 20230258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
